.jpg)
USE OF A NEUROPEPTIDE IN THE PREVENTION AND / OR TREATMENT OF DISORDERS AND EFFECTS RELATED TO ALCOHOL.
WO19068948
Alcohol is one of the drugs with the highest consumption globally, being responsible for a large number of health-related problems. Despite the great socio-economic impact that alcohol consumption entails, there is a lack of effective treatments for its addiction. Recently, neuropeptides are being considered as key pieces in some neuropsychiatric diseases, among which is alcoholism, and therefore, key targets where to find new treatments. In recent studies in animal models, the use of the Galanin fragment (1-15) is proposed as a therapy capable of producing a decrease in voluntary alcohol consumption as well as a great decrease in the preference for this substance. Specifically, the present invention proposes the use of Galanin (1-15) to rapidly decrease the preference and consumption of alcohol in people with abusive alcohol use.
Currently, there are only three drugs approved for the treatment of alcoholism, but none of them is certainly effective. The appearance of a new drug capable of reducing the preference and consumption of alcohol quickly, as demonstrated in pre-clinical studies, would be a great advantage for the treatment of alcoholism and its associated pathologies. Given that the effect of Galanin (1-15) in alcoholism seems to be related to a depletion of the natural reinforcement system, its use would not only help to reduce the consumption of alcohol but also of other substances of abuse that are consumed together with is. Pharmaceutical sector. Applications in the treatment of addiction to alcohol and other drugs of abuse.